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Abstract
Rapid advancement of next-generation sequencing (NGS) technologies has facilitated the search 
for genetic susceptibility factors that influence disease risk in the field of human genetics. In 
particular whole genome sequencing (WGS) has been used to obtain the most comprehensive 
genetic variation of an individual and perform detailed evaluation of all genetic variation. To this 
end, sophisticated methods to accurately call high-quality variants and genotypes simultaneously 
on a cohort of individuals from raw sequence data are required. On chromosome 22 of 818 WGS 
data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), which is the largest WGS 
related to a single disease, we compared two multi-sample variant calling methods for the 
detection of single nucleotide variants (SNVs) and short insertions and deletions (indels) in WGS: 
(1) reduce the analysis-ready reads (BAM) file to a manageable size by keeping only essential 
information for variant calling (“REDUCE”) and (2) call variants individually on each sample and 
then perform a joint genotyping analysis of the variant files produced for all samples in a cohort 
(“JOINT”). JOINT identified 515,210 SNVs and 60,042 indels, while REDUCE identified 358,303 
SNVs and 52,855 indels. JOINT identified many more SNVs and indels compared to REDUCE. 
Both methods had concordance rate of 99.60% for SNVs and 99.06% for indels. For SNVs, 
evaluation with HumanOmni 2.5M genotyping arrays revealed a concordance rate of 99.68% for 
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JOINT and 99.50% for REDUCE. REDUCE needed more computational time and memory 
compared to JOINT. Our findings indicate that the multi-sample variant calling method using the 
JOINT process is a promising strategy for the variant detection, which should facilitate our 
understanding of the underlying pathogenesis of human diseases.
Introduction
Recent large-scale genome-wide association studies (GWAS) have identified and confirmed 
many susceptibility genes associated with human diseases and traits.1-3 However, only a 
small portion of their heritability is accounted for by all of the known susceptibility genes 
leaving a substantial proportion of the heritability remaining to be identified.4, 5 Next-
generation sequencing (NGS) may enable discovery of novel genetic underpinnings that 
account for some of the missing heritability.6, 7 Rapid advancement of next-generation 
sequencing (NGS) technologies has facilitated the search for genetic susceptibility factors 
that influence disease risk and become a key technique for detecting pathogenic variants in 
human diseases.8, 9 Several sequencing-based association studies could identify functional 
risk variants with large effects on human disease pathogenesis within genes.10 Accumulating 
evidence shows that common and rare risk variants are likely to co-exist at the same locus 
(known as pleomorphic risk loci).11
In particular, whole-genome sequencing (WGS) has been used to obtain the most 
comprehensive genetic variation of an individual and perform detailed evaluation of all 
genetic variation.12 To this end, sophisticated methods to accurately call high-quality 
variants and genotypes simultaneously on a cohort of individuals from raw sequence data 
are required. Therefore, numerous methods have been proposed for high-throughput short 
read alignment and variant calling.13 Still highly accurate variant calling is one of the most 
important challenges. The reduction in the cost of sequencing a human genome has led make 
possible to sequence many samples completely. As multi-sample variant callings can use 
additional information from multiple samples at a single site, multi-sample variant callings 
are thought to have advantages compared to single-sample variant calling.14 However, the 
file size is a major roadblock for data analysis scalability, and multi-sample variant callings 
can require considerable computing time and resources. Therefore multi-sample variant 
calling methods are under active development.
Here we compared two multi-sample variant calling methods for the detection of single 
nucleotide variants (SNVs) and short insertions and deletions (indels) in WGS on 
chromosome 22 of 818 WGS data from the Alzheimer's Disease Neuroimaging Initiative 
(ADNI). The first type of multi-sample variant caller is to reduce the analysis-ready reads 
(BAM) file to a manageable size by keeping only essential information for variant calling 
that allows greater performance and scalability for multi-sample variant callers. The second 
type of multi-sample variant caller is to first call variants individually on each sample to 
produce a comprehensive record of genotype likelihoods and annotations for each site in the 
genome and then perform a joint genotyping analysis of the variant files produced for all 
samples in a cohort (www.broadinstitute.org/gatk/).
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Materials and Methods
Subjects
All individuals used in this report were participants of the Alzheimer's Disease 
Neuroimaging Initiative Phase 1 (ADNI-1) and/or its subsequent extension (ADNI-GO/2). 
The initial phase (ADNI-1) was launched in 2003 to test whether serial magnetic resonance 
imaging (MRI), position emission tomography (PET), other biological markers, and clinical 
and neuropsychological assessment could be combined to measure the progression of MCI 
and early AD. The ADNI-1 participants were recruited from 59 sites across the U.S. and 
Canada and include approximately 200 cognitively normal older individuals (healthy 
controls (HC)), 400 patients diagnosed with MCI, and 200 patients diagnosed with early 
probable AD aged 55-90 years. ADNI-1 has been extended to its subsequent phases (ADNI-
GO and ADNI-2) for follow-up for existing participants and additional new enrollments. 
Inclusion and exclusion criteria, clinical and neuroimaging protocols, and other information 
about ADNI have been published previously and can be found at www.adni-info.org. 
Demographic information, raw scan data, APOE and whole genome sequencing data, 
neuropsychological test scores, and diagnostic information are available from the ADNI data 
repository (http://www.loni.usc.edu/ADNI/). Written informed consent was obtained at the 
time of enrollment for imaging and genetic sample collection and protocols of consent forms 
were approved by each participating sites’ Institutional Review Board (IRB).
Whole genome sequencing (WGS) analysis
WGS was performed on blood-derived genomic DNA samples obtained from 818 ADNI 
participants. Samples were sequenced on the Illumina HiSeq2000 using paired-end read 
chemistry and read lengths of 100bp (www.illumina.com). The resulting Illumina qseq files 
were converted into fastq files, a text-based format for storing both sequence reads and their 
corresponding quality information in Phred format. Short-read sequences were mapped to 
the NCBI reference human genome (build 37) using BWA, allowing for up to two 
mismatches in each read. During the alignment, we use only bases with Phred Quality > 15 
in each read to include soft clipping of low-quality bases, retain only uniquely mapped pair-
end reads, and remove potential PCR duplicates. After completing initial alignment, the 
alignment is further refined by locally realigning any suspicious reads. The reported base 
calling quality scores obtained from the sequencer are re-calibrated to account for covariates 
of base errors such as sequencing technology and machine cycle. Finally, the realigned reads 
are written to a BAM file for further analysis (see Figure 1). Variant Discovery: The 
analysis-ready BAM files are analyzed to identify all variants with statistical evidence for an 
alternate allele present among samples using the HaplotypeCaller module of GATK for 
multi-sample variant callings. The first type of multi-sample variant caller is to reduce the 
analysis-ready reads (BAM) file to a manageable size by keeping only essential information 
for variant calling that allows greater performance and scalability for multi-sample variant 
callers (“REDUCE”). The second type of multi-sample variant caller is to first call variants 
individually on each sample to produce a comprehensive record of genotype likelihoods and 
annotations for each site in the genome and then perform a joint genotyping analysis of the 
variant files produced for all samples in a cohort (“JOINT”). The HaplotypeCaller module of 
GATK calls SNVs and indels simultaneously via local de-novo assembly of haplotypes in an 
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active region. The quality of the variant calls was assessed by comparing sequencing-
derived SNVs with those obtained from the Illumina Omni 2.5M genotyping array in order 
to estimate the concordance rate. Among 818 subjects, two subjects had concordance rates 
less than 99% and had been removed from our analysis.
Results
We used a same pre-calling procedure and two different multi-sample variant calling 
methods to identify SNVs and indels from 818 ADNI WGS data. First we compared the 
numbers of SNVs and indels across two multi-sample variant callers. Figure 2 and Table 1 
summarized the distribution of the number of SNVs and indels identified using two different 
callers.
The final variant file (VCF) indicated that the mean depth of mapped unique reads (after 
removing reads with more than two mismatches in each read) at all identified variants on 
chromosome 22 are 24.6X for JOINT. JOINT identified 515,210 SNVs and 60,042 indels, 
while REDUCE identified 358,303 SNVs and 52,853 indels. For the JOINT SNVs, 8,594 
exonic SNVs, of which 4,650 SNVs (54.1%) are non-synonymous, were found in the 
protein-coding regions. For the REDUCE SNVs, 5,458 SNVs, of which 2,908 SNVs 
(53.3%) are non-synonymous, were found in the protein-coding regions. JOINT increased 
the proportion of called variants, i.e., identified 43% and 14% more SNVs and indels 
compared to REDUCE. 98.1% (351,648 SNVs) and 91.0% (48,101 indels) of the REDUCE 
SNV and indel calls, respectively, are also present in the JOINT set. The concordance ratios 
of the common SNVs and indels from two caller methods are 99.60% and 99.06%, 
respectively. The observed transition-to-transversion ratios for the SNV sets on chromosome 
22 for JOINT and REDUCE are 2.39 and 2.36, respectively. In order to assess the quality of 
the variant calls, we compared sequencing-derived SNVs with those obtained from the 
Illumina Omni 2.5M genotyping array and overall genotype consistency rates are 99.7% for 
the JOINT SNV set and 99.5% for the REDUCE SNV set.
Discussion
Our understanding of the association of the genetic variation with human disease has been 
greatly advanced using high-throughput NGS technologies. NGS has become a powerful 
tool for explaining the missing heritability of human diseases through rare and de novo 
variants. One of the most important challenges in NGS analysis is to accurately call high-
quality variants (SNVs and indels) and genotypes simultaneously on a cohort of individuals 
from raw sequence data and is still under an active research topic. Multi-sample variant 
callings have been shown to have more advantages than the corresponding single-sample 
variant callings. However, under current computing resources, it is not possible to call multi-
sample variants using all mapped reads simultaneously from 818 WGS. Here we compared 
two multi-sample variant calling methods for SNVs and indels on chromosome 22 of 818 
WGS data from ADNI, which is the largest WGS related to a single disease.
The JOINT method identified much more SNVs and indels, and required considerably less 
computation time and resources. The JOINT method identified 43% more SNVs, although 
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the JOINT method identified 14% more indels. In particular, 98.1% and 91.0% of SNVs and 
indels identified by the REDUCE method were also called by the JOINT method with more 
than 99% concordance. Both methods showed very high concordance with both each other 
and the Illumina Omni 2.5M genotyping array. The concordance analysis indicated that the 
JOINT method performed considerably better than the REDUCE method.
In conclusion, our data indicate that the multi-sample variant calling method to first call 
variants individually on each sample in order to produce a comprehensive record of 
genotype likelihoods and annotations for each site in the genome and then perform a joint 
genotyping analysis of the variant files produced for all samples in a cohort is a promising 
strategy for the variant detection. As the development of multi-sample variant calling 
methods is a rapidly evolving target, these methods will require frequent re-evaluation for 
further improvement.
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Fig 1. Whole Genome Sequencing Analysis Pipeline
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Fig 2. Variants (SNVs and indels) identified on chromosome 22 of 816 genomes by two multi-
sample variant calling methods
Nho et al. Page 8
IEEE Int Conf Systems Biol. Author manuscript; available in PMC 2015 July 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Nho et al. Page 9
Table 1
Numbers of identified SNVs and indels on chromosome 22 of 816 genomes
SNV only INDEL only
JOINT REDUCE JOINT REDUCE
Exonic 8,594 5,458 184 177
Intergenic 233,991 164,549 27,170 23,430
Intronic 226,289 156,430 27,156 24,195
Splicing 57 35 8 8
UTR 3′ 7,984 5,508 944 893
UTR 5′ 1,834 1,142 167 156
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